Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk [Yahoo! Finance]
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
The prospective multicenter DECIDE study validated Castle's 31-gene DecisionDx-Melanoma test and its model outputs ( i31-SLNB and i31-ROR ), showing strong stratification of sentinel lymph node positivity (2.6% for 10%; Stage IB: 1.4% vs 18.5% for low vs high predicted risk). DECIDE showed clinical utility: patients with low predicted nodal risk who avoided SLNB had a 97.8% three-year recurrence-free survival and low false-negative rates (2.6% overall; 1.8% in T1/T2a), supporting use of the test to reduce unnecessary SLNB. Castle positions DECIDE as adding prospective multicenter evidence to prior studies and real-world data, and reports that clinically tested patients had a 32% lower three-year melanoma-specific mortality versus untested patients, which the company cites to argue improved survival association. Interested in Castle Biosciences, Inc.? Here are five stocks we like better. Castle Biosciences (NASDAQ:CSTL) executives and clinical collaborators used a DecisionDx-M
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript [Seeking Alpha]Seeking Alpha
- Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets [Yahoo! Finance]Yahoo! Finance
- Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB [Yahoo! Finance]Yahoo! Finance
- Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNBGlobeNewswire
- SciBase: Interim report [Yahoo! Finance]Yahoo! Finance
CSTL
Earnings
- 2/26/26 - Beat
CSTL
Sec Filings
- 3/19/26 - Form 4
- 3/17/26 - Form 4
- 3/16/26 - Form 4
- CSTL's page on the SEC website